In vivo antithrombotic properties of a heparin from the oocyte test cells of the sea squirt Styela plicata (Chordata-Tunicata)

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 11, 2006, Pages 1409-1415

  Cardilo Reis, L ^a   Cavalcante, M C M ^a   Silveira, C B M ^a   Pavao M S G ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antithrombotics; Ascidian; Experimental thrombosis; Hemorrhage; Heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; HEPARIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; ASCIDIACEA; BLEEDING; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG ISOLATION; FEMALE; IN VIVO STUDY; MALE; NONHUMAN; OOCYTE; PARTIAL THROMBOPLASTIN TIME; RAT; STYELA PLICATA; VEIN THROMBOSIS; WISTAR RAT;

ASCIDIA; CHORDATA; MAMMALIA; RATTUS; RATTUS NORVEGICUS; STYELA PLICATA; SUS; UROCHORDATA;

EID: 33847627999     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006001100004     Document Type: Article

References (23)

1. Kjellén L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991; 60: 443-475.
2. Conrad HE. Heparin binding proteins. Sari Diego. Academic Press, 1998.
3. McLean J. The thromboplastic action of cephalin. Am J Physiol 1916; 41: 250-257.
4. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255: 10081-10090.
5. Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 1983; 309: 954-958.
6. Poller L. Therapeutic ranges in anticoagulant administration. Br Med J 1985; 290: 1683-1686.
7. Straus AH, Nader HB, Dietrich CP. Absence of heparin or heparin-like compounds in mast-cell-free tissues and animals. Biochim Biophys Acta 1982; 717: 478-485.
8. Cassaro CM, Dietrich CP. Distribution of sulfated mucopolysaccharides in invertebrates. J Biol Chem 1977; 252: 2254-2261.
9. Medeiros GF, Mendes A, Castro RA, Bau EC, Nader HB, Dietrich CP. Distribution of sulfated glycosaminoglycans in the animal kingdom: widespread occurrence of heparin-like compounds in invertebrates. Biochim Biophys Acta 2000; 1475: 287-294.
10. Burson SL, Fahrenbach MJ, Frommhagen LH, Riccardi BA, Brown RA, Brockman JA, et al. Isolation and purification of mactins heparin-like anticoagulants from mollusca. J Am Chem Soc 1956; 78: 5874-5878.
11. Rahemtulla F, Lovtrup S. The comparative biochemistry of invertebrate mucopolysaccharides - VI. Crustacea. Comp Biochem Physiol B 1976; 53: 15-18.
12. Cavalcante MC, Allodi S, Valente AP, Straus AH, Takahashi HK, Mourao PA, et al. Occurrence of heparin in the invertebrate Styela plicata (Tunicata) is restricted to cell layers facing the outside environment. An ancient role in defense? J Biol Chem 2000; 275: 36189-36196.
13. Vogel GM, Meuleman DG, Bourgondien FG, Hobbelen PM. Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans. Thromb Res 1989; 54: 399-410.
14. Herbert JM, Héralt JP, Bernat A, Van Amsterdan RGM, Vogel GMT, Lormeau JC, et al. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide (SR 90107/org 31540)" and standard heparin. Circ Res 1996; 79: 590-600.
15. Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485.
16. Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 1982; 47: 244-248.
17. Thomas DP, Merton RE, Gray E, Barrowcliffe TW. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemost 1989; 61: 204-207.
18. Bagge L, Wahlberg T, Holmer E, Tyden H, Nystrom SO, Malm T. Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model, Blood Coagul Fibrinolysis 1994; 5: 265-272.
19. Colwell CW Jr. Recent advances in the use of low molecular weight heparins as prophylaxis for deep vein thrombosis. Orthopedics 1994; 17 (Suppl): 5-7.
20. Haas S, Flosbach CW. Prevention of postoperative thromboembolism with Enoxaparin in general surgery: a German multicenter trial. Semin Thromb Hemost 1993; 19 (Suppl 1): 164-173.
21. Hirsh J. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Haemostasis 1996; 26 (Suppl 4): 189-198.
22. Vicente CP, Zancan P, Peixoto LL, ves-Sa R, Araujo FS, Mourao PA, et al. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding. Thromb Haemost 2001; 86: 1215-1220.
23. Farias WR, Nazareth RA, Mourao PA. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation. Thromb Haemost 2001; 86: 1540-1546.